SCHEMBL11897675

SCHEMBL11897675

O=[N+]([O-])c1ccc(N=C(Cl)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.54
CES1 P23141 1/20 0.54
PLAU P00749 1/20 0.54
NOS1 P29475 5/20 0.53
ALDH1A1 P00352 4/20 0.49
LMNA P02545 1/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NOS3 P29474 3/20 0.47
RAB9A P51151 3/20 0.47
POLB P06746 2/20 0.47
NPC1 O15118 2/20 0.47
MITF O75030 1/20 0.47
MAPK1 P28482 3/20 0.46
MAPT P10636 2/20 0.46
CASP3 P42574 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11897674 1.00 CES2 (0.54) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL7460429 0.93 CES1 (0.54) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL5609313 0.83 CES2 (0.58) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL18100425 0.82 MEN1 (0.48) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL9423002 0.80 RAB9A (0.52) PLAUNOS1ALDH1A1LMNAMEN1
SCHEMBL9423004 0.80 RAB9A (0.52) PLAUNOS1ALDH1A1LMNAMEN1
SCHEMBL4869749 0.80 PLAU (0.64) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL11126692 0.80 NOS1 (0.62) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL4624494 0.78 KMT2A (0.54) CES2CES1PLAUNOS1ALDH1A1
SCHEMBL4624489 0.78 KMT2A (0.54) CES2CES1PLAUNOS1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604947-B2 Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2017-03-28 US disclosed
US-20120225879-A1 SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFACAS ( CSIC) (ES) 2012-09-06 US disclosed
EP-2484670-A1 SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2012-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225879-A1 SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES PDE7B, PDE7A, PARK7 CES2 1234/4885CES1 645/4885PLAU 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.